Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
458 active trials5 approved drugs36 evidence items
- NCIt
- C181162
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Clinical trials
1,481 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06084780 | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)(TRANSCAPE) | not yet recruiting | Phase 2 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT07265739 | Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer | not yet recruiting | Phase 2 | 27 | Massachusetts General HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial(SIERRA) | not yet recruiting | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT06708351 | Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial | not yet recruiting | N/A | 2,280 | Emory UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07825181 | Homologous Recombination Repair Deficiency (HRD) Testing in Newly Diagnosed Advanced-stage Epithelial Ovarian Cancer in Italy(HRD-Italy) | not yet recruiting | — | 1,125 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07764744 | Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants(OC-LEAD) | not yet recruiting | N/A | 70 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07811271 | Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers | not yet recruiting | Phase 3 | 600 | BeOne MedicinesINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer(TIDE) | not yet recruiting | Early Phase 1 | 15 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | not yet recruiting | Phase 2 | 42 | Washington University School of MedicineOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07791732 | A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03) | not yet recruiting | Phase 3 | 600 | Daiichi SankyoINDUSTRY | 0 | Sep 1, 2026 | clinicaltrials |
| NCT07753824 | A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) | not yet recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790939 | 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer | not yet recruiting | Early Phase 1 | 20 | Peking University Cancer Hospital & InstituteOTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | not yet recruiting | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer(MELIA) | not yet recruiting | Phase 2 | 128 | Tongji HospitalOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07776171 | Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 176 | Sun Yat-sen UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07772882 | Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer | not yet recruiting | Phase 1 | 24 | Rebecca ArendOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06607874 | Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida | not yet recruiting | — | 100 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07281547 | Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain | not yet recruiting | Phase 4 | 20 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | not yet recruiting | Phase 2 | 2 | Verastem, Inc.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07738315 | Elemene Liposomes in Endometrial Cancer | not yet recruiting | Phase 2 | 212 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07723235 | Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial | not yet recruiting | N/A | 90 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07715747 | A Phase I Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 128 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07674615 | IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer | not yet recruiting | Phase 1 | 19 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675733 | A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility(SHORTEN) | not yet recruiting | N/A | 30 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07545460 | A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | not yet recruiting | Phase 3 | 404 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | not yet recruiting | Phase 2 | 28 | GOG FoundationNETWORK | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07664735 | A Phase 1 Study to Evaluate the Safety and Efficacy of OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer. | not yet recruiting | Phase 1 | 30 | Outpace Bio, Inc.INDUSTRY | 0 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | not yet recruiting | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07613567 | A Clinical Study of QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical Cancer | not yet recruiting | Phase 3 | 486 | Fujian Cancer HospitalOTHER_GOV | 1 | May 29, 2026 | clinicaltrials |
| NCT07583329 | Comparison of Sentinel Lymph Node Applications in Endometrial Cancer Cases Performed With Vaginal Natural Orifice Transluminal Endoscopic Surgery (V-NOTES) and Conventional Laparoscopy(V-COSMOS) | not yet recruiting | — | 160 | Cukurova UniversityOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07591831 | Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 18, 2026 | clinicaltrials |
| NCT07593339 | Sentinel Lymph Node Mapping in Early-Stage Epithelial Ovarian Cancer Surgery | not yet recruiting | N/A | 30 | Başakşehir Çam & Sakura City HospitalOTHER_GOV | 0 | May 18, 2026 | clinicaltrials |
| NCT07461142 | Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers(RETHEMCOL) | not yet recruiting | N/A | 72 | Institut Paoli-CalmettesOTHER | 0 | Mar 10, 2026 | clinicaltrials |
| NCT07454018 | Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer | not yet recruiting | Phase 2 | 45 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Mar 6, 2026 | clinicaltrials |
| NCT07432594 | Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer | not yet recruiting | Phase 2 | 82 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07378371 | Proactive Temperature Management in CRS-HIPEC for Prevention of Delirium | not yet recruiting | N/A | 174 | Aerospace Center HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07374809 | IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER(DEMETER) | not yet recruiting | N/A | 50 | European Institute of OncologyOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07368985 | Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer | not yet recruiting | Phase 2 | 87 | Prof. Dr. Remi A. NoutOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07295132 | RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) | not yet recruiting | Phase 2 | 160 | Asan Medical CenterOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07269574 | Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi Maintenance | not yet recruiting | — | 600 | Tongji HospitalOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07267780 | Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases. | not yet recruiting | — | 130 | National Cancer Institute, NaplesOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07268469 | Minimal Residual Disease in Solid Malignancies(IMRD) | not yet recruiting | N/A | 840 | European Institute of OncologyOTHER | 0 | Dec 5, 2025 | clinicaltrials |
| NCT07057167 | Prediction of Ovarian Cancer Histotypes and Surgical Outcome(PANtHer-AI) | not yet recruiting | — | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT06861855 | Prognosis of METTL-14 in Endometrial Carcinoma | not yet recruiting | — | 50 | Assiut UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07088731 | Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 180 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 22, 2025 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials